Skip to main content
. 2016 Aug 19;7(38):62280–62291. doi: 10.18632/oncotarget.11409

Figure 5.

Figure 5

A. Disease monitoring in two patients with no recurrence during follow-up using targeted sequencing of cfDNA; changes in conventional biomarkers and AFs of concordant mutations for case 9; AFs of non-concordant mutations were not detected in serial plasma. B. Changes in conventional biomarkers and AFs of mutations detected only in primary tumor samples from case 1.